Grifols S.A. Sponsored ADR (GIKLY)
OTC PINK 
Summary
Grifols S.A. Sponsored ADR Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| MD Michelle Dubey Yousif Capital Management LLC | 13,202 | $122,646.58 | $67,330.2 | -$55,316.38 | -45.1% |
Grifols S.A. Sponsored ADR (GIKLY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Grifols S.A. Sponsored ADR ever had a stock split?
Grifols S.A. Sponsored ADR Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Mr. Jose Ignacio Abia Buenache CEO | OTC PINK Exchange | 398438200 CUSIP |
| DE Country | 25,258 Employees | 2 Jul 2026 Last Dividend | - Last Split | - IPO Date |
Overview
Grifols, S.A., headquartered in Barcelona, Spain, is a leading company in the plasma therapeutics industry, boasting a comprehensive presence across Spain, the United States, Canada, and numerous international markets. Since its establishment in 1909, the company has dedicated itself to the innovation and provision of a broad spectrum of plasma-derived products, diagnostics, pharmaceutical products for hospital pharmacies, and advanced research and development activities. With a strong emphasis on serving patients with rare and chronic conditions, Grifols has established a robust portfolio of products and services, underpinned by strategic collaborative agreements with entities like Canadian Blood Services, GIANT, and GigaGen to enhance its offerings and research capabilities in recombinant polyclonal immunoglobulin therapies.
Products and Services
- Plasma-Derived Products:
Grifols offers a wide array of plasma-derived products addressing critical medical needs. These include immunoglobulins for immunodeficiencies, albumin for restoring circulatory volume, and alpha-1 proteinase inhibitor for treating alpha-1 antitrypsin deficiency. The portfolio also encompasses clotting factors like factorVIII/von Willebrand factor and factor IX for hemophilia and von Willebrand's disease, along with antithrombin III for hereditary antithrombin deficiency.
- Pharmaceutical Products:
The company markets a range of pharmaceutical products intended primarily for hospital pharmacies. This category includes Yimmugo PID, an immunology drug; Yimmugo ITP for hematology; Fostamatinib, a spleen tyrosine kinase inhibitor; and various other formulations aimed at managing complex conditions.
- Diagnostic Equipment and Reagents:
Grifols is also involved in the marketing of diagnostic testing equipment, reagents, and other related medical equipment, enhancing the ability of healthcare professionals to diagnose and treat diseases effectively.
- Research and Development:
The company is actively engaged in research activities aiming to develop innovative treatments and products. Current projects include Xembify Pre-filled syringes, FlexBag, and Prolastin vials in phase IV; and an extensive range of products in various stages of development aimed at treating a wide spectrum of diseases, showcasing Grifols’ commitment to advancing healthcare solutions.
- Collaborative Agreements:
Grifols has entered into collaboration agreements with high-profile entities such as Canadian Blood Services and GigaGen, focusing on the processing of plasma-derived products and the development of recombinant polyclonal immunoglobulin therapies, respectively. These partnerships underscore the company's strategic approach to leveraging external expertise and resources in its quest to bring innovative therapies to market.
